| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to establish methods to measure anti-M-type phospholipase A2 receptor (PLA2R) antibodies, specific markers of primary membranous nephropathy (MN), and assess their clinical usefulness. We developed a western blot assay and a cell-based enzyme-linked immunosorbent assay (ELISA). Anti-PLA2R antibodies were detected in 52% of the patients with biopsy-proven primary MN using the western blot. The levels of proteinuria correlated with the anti-PLA2R antibody titers measured by the three methods. Anti-PLA2R antibodies were significantly associated with physicians’ decisions on immunosuppressive treatment. The titers of anti-PLA2R antibodies declined significantly following treatment. These results suggest the usefulness of anti-PLA2R antibody as a diagnostic, prognostic, and surrogate biomarker in primary MN. The three methods proved to be reliable, but their performances differ.
|
